Now showing items 1-3 of 3

    • Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. 

      Payne, H; Adamson, A; Bahl, A; Borwell, J; Dodds, D; Heath, C; Huddart, R; McMenemin, R; Patel, P; Peters, JL; Thompson, A (2013-11)
      • To review the published data on predisposing risk factors for cancer treatment-induced haemorrhagic cystitis (HC) and the evidence for the different preventive and therapeutic measures that have been used in order to ...
    • Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. 

      Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Alimam, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa, R; McMullin, MF (2017-10)
      Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis, and leukemia. Patients resistant/intolerant ...
    • Trans-abdominal in vivo placental vessel occlusion using High Intensity Focused Ultrasound. 

      Shaw, CJ; Rivens, I; Civale, J; Botting, KJ; Ter Haar, G; Giussani, DA; Lees, CC (2018-09-11)
      Pre-clinically, High Intensity Focused Ultrasound (HIFU) has been shown to safely and effectively occlude placental blood vessels in the acute setting, when applied through the uterus. However, further development of the ...